| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT02995642 Details | 2021-05-21 Interventional | 2 | 0 | Arginyl-glycyl-… Aneurysm Aortic Aneurysm Aortic Aneurysm… Atherosclerosis Carotid Artery … Inflammation Carotid Atheros… | Resources not secured - | |||
| NCT02056288 Details | 2021-05-21 Interventional | 4 | 78 | Fentanyl Ropivacaine Fractures, Bone Supracondylar F… | Enrollment was suspended due to the duration of the study and poor follow-up response by
participants. - | |||
| NCT03540160 2017-004211-40 Details | 2021-05-20 Interventional | 3 | 558 | Serlopitant Dermatitis Prurigo Pruritus Psoriasis Atopic Dermatit… Prurigo Nodular… | No longer pursuing development of serlopitant Due to a corporate decision to no longer pursue an indication of treatment for pruritus, and further to terminate the development program for serlopitant, the study was terminated prematurely. | |||
| NCT02975271 Details | 2021-05-20 Interventional | 2 | 1 | Serlopitant Burns Pruritus | Business Reasons - | |||
| NCT02966184 Details | 2021-05-20 Interventional | 4 | 8 | Albuterol Status Asthmati… | Study Drug Backorder - | |||
| NCT02693717 Details | 2021-05-20 Interventional | 2 | 7 | Pemetrexed Carcinoma Carcinoma, Tran… Metastatic Urot… | The trial was closed due to the changing efficacy of treatments for metastatic urothelial
cancer. This protocol was stopped early as it was considered unethical. A new protocol with the same study drugs plus an immune check point drug was added. There is no data to report. | |||
| NCT01131325 Details | 2021-05-20 Interventional | 4 | 3 | Nilotinib Leukemia Leukemia, Myelo… Leukemia, Myelo… Philadelphia Ch… CML Chronic Myeloge… Philadelphia Ch… | - The study was terminated early due to slow enrollment. | |||
| NCT01736579 Details | 2021-05-19 Interventional | 3 | 6 | Antibodies Immunoglobulins Immunoglobulins… Rho(D) Immune G… gamma-Globulins Alzheimer Disea… Alzheimer´s Di… | The study was terminated because the first Phase 3 did not demonstrate efficacy on the
co-primary endpoints. The known safety profile remained unchanged. This study was an extension of study 160701 and was stopped early due to lack of evidence of clinical benefit of IGIV treatment in Alzheimer's Disease patients in Baxalta study 160701. Summary tables available for safety data only. | |||
| NCT00582205 Details | 2021-05-19 Interventional | 2 | 21 | Cisplatin Paclitaxel Carcinoma Carcinoma, Ovar… Fallopian Tube … Ovarian Neoplas… Uterine Neoplas… Fallopian Tube … Ovarian Cancer Primary Periton… Uterine Cancer | Study completed per investigator. - | |||
| NCT02514252 Details | 2021-05-18 Interventional | 2 | 6 | Fentanyl Breakthrough Pa… Advanced Cancer… | - - | |||
| NCT02055690 2013-005471-40 Details | 2021-05-17 Interventional | 1/2 | 21 | Fosbretabulin Carcinoma, Ovar… Neoplasms Ovarian Neoplas… Neoplasms, Ovar… Ovarian Cancer | Safety - | |||
| NCT02047539 Details | 2021-05-17 Interventional | 1 | 1 | Aspirin Mental Disorder… Psychotic Disor… Clinical High R… | - - | |||
| NCT04818736 Details | 2021-05-14 Interventional | 4 | 0 | Vaccines Vaccine-Prevent… Vaccine Prevent… | Vaccine roll out plans increased so timing was no longer feasible - | |||
| NCT00985621 2009-013329-41 Details | 2021-05-14 Interventional | 3 | 614 | Oxycodone Tanezumab Osteoarthritis | See termination reason in detailed description. Due to the US FDA imposed clinical hold (effective 23 June 2010), study was terminated early and planned sample size was not reached. The primary time-point was changed from Week 16 to Week 8, as per change in planned analysis. | |||
| NCT03786419 Details | 2021-05-13 Interventional | 2 | 0 | Atezolizumab Mesothelioma Mesothelioma, M… Malignant Pleur… Malignant Pleur… | Publication of study results of ICI use in MPM as first line therapy - | |||
| NCT02722304 Details | 2021-05-13 Interventional | 3 | 7 | Alpha 1-Antitry… Protease Inhibi… Alpha 1-Antitry… Lung Diseases Lung Diseases, … Pulmonary Disea… Alpha1-antitryp… Chronic Obstruc… | - The Data Monitoring Committee (DMC) reviewed the available efficacy and safety data and unanimously recommended to terminate the study. The decision was based on the very low number of enrollees, and the slow rate of participant enrollment. | |||
| NCT02429934 Details | 2021-05-13 Interventional | 1/2 | 28 | Abatacept Arthritis Lupus Erythemat… Systemic Lupus … | Response rate in placebo group for primary outcome was 100% on interim analysis. - | |||
| NCT00994890 Details | 2021-05-13 Interventional | 2 | 679 | Tanezumab Osteoarthritis Osteoarthritis,… Osteoarthritis,… | See termination reason in detailed description. Due to United States FDA imposed clinical hold, enrollment was stopped and study was terminated prematurely. Due to this, injection-site reaction data were not collected beyond Week 40 and NIS data were not collected beyond Week 48. | |||
| NCT04854044 Details | 2021-05-12 Interventional | 1 | 0 | TIC10 compound Glioblastoma Gliosarcoma Recurrence Recurrent Gliob… Recurrent Glios… Recurrent Supra… Supratentorial … | The P.I. is not prepared to move forward at this thime - | |||
| NCT04359511 Details | 2021-05-12 Interventional | 3 | 0 | Hydrocortisone Prednisone COVID-19 Pneumonia | COMPETITOR TEST (RECOVERY) - |